Exolaunch Secures Starfall Reentry Contract
German integrator Exolaunch enters the Earth-return market, booking 1,000 kg of payload capacity on SpaceX's Starfall mission for pharmaceutical and biotech clients.
# Orbital Logistics: Exolaunch Taps Starship
German payload integrator Exolaunch has formally expanded its operational scope into the reentry sector. The Berlin-based firm announced an agreement to support customer payloads on a SpaceX Starfall mission, currently scheduled for no earlier than 2029.
According to Payload, this deal represents a dual milestone: Exolaunch’s inaugural commitment to the Starship platform and its first venture into Earth-return logistics. The mission targets a 1,000 kg payload capacity, which Exolaunch intends to fill with biotech, pharmaceutical, and in-space manufacturing hardware.
Strategic Scaling
To facilitate this shift, Exolaunch is evaluating the acquisition or development of proprietary hardware to secure payloads within the Starship vehicle. Chief Marketing Officer Jeanne Allarie noted that the firm will manage the end-to-end technical, regulatory, and logistical hurdles inherent in reentry operations.
Financial backing is expected to accelerate these plans. Global investment firm EQT is set to acquire Exolaunch by Q4 2026. This acquisition provides Exolaunch with direct access to EQT’s extensive portfolio of biotech firms, potentially streamlining the customer pipeline for microgravity research.
The Reentry Landscape
Exolaunch joins a growing roster of European and international entities securing space on the Starfall program. Other notable bookings include:
- Redwire’s SpaceMD: Scheduled for 2028 with 32 PIL-BOX variants for drug development.
- Space Cargo Unlimited: A 2028 manufacturing facility mission, which is already 30% sold out.
By leveraging its existing relationship with SpaceX’s Transporter program, Exolaunch aims to dominate the emerging market for scalable, returnable orbital assets.